Captura Biopharma

About:

Captura Biopharma is an emerging biotechnology company engaged in the development and commercialization of heavy metal chelators.

Website: https://www.capturabiopharma.com/

Top Investors: The Global Emerging Markets Group

Description:

Captura Biopharma is an biotechnology company engaged in the development and commercialization of heavy metal chelators useful in the treatment of internal radionuclide contamination and heavy metal poisoning. Its lead chelation candidate, C2E2, will be the world's first oral treatment indicated for internal radiation contamination and has been proven in efficacy studies to target select heavy metals, notably americium, plutonium, and lead. Heavy metal contamination, including exposure to transuranic elements, is on the rise.

Total Funding Amount:

$50M

Headquarters Location:

Little Rock, Arkansas, United States

Founded Date:

2019-01-01

Contact Email:

michael(AT)capturabiopharma.com

Founders:

Anthony Soscia, Michael Geranen

Number of Employees:

1-10

Last Funding Date:

2021-08-18

IPO Status:

Private

Industries:

© 2025 bioDAO.ai